5-year Longitudinal Observational Study of Patients Undergoing Therapy for

IMISC (TARGET-DERM)

 

Reference NCT03661866

 

Estimated Study Completion Date December 31, 2026

 

Target PharmaSolutions, Inc.

Brief Summary:

TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

 

For complete details see link below:

 

https://clinicaltrials.gov/ct2/show/NCT03661866?cond=Hidradenitis+Suppurativa&cntry=US&draw=3&rank=45

 

Several statewide locations. Contact below to inquire about participation.

Contact: Laura Dalfonso 9842340268

Email: ldalfonso@targetpharmasolutions.com

 

Contact: Laura Malahias 9842340268 ext 209

Email: lmalahias@targetpharmasolutions.com

Get Updates

Affiliated With

  • Instagram
  • Twitter
  • Facebook Social Icon
  • Pinterest

© 2020 by HS Connect   |  HSConnect.org@gmail.com  |  Hidradenitis Suppurativa Online

PO Box 73244 Puyallup, WA 98373  |  253.256.1579